I have so many unanswered questions. 1. AVDX f
Post# of 30027
Posted On: 09/06/2016 1:49:18 PM
I have so many unanswered questions.
1. AVDX filed its Exchange Agreement with the SEC and it included this:
"Agreement regarding Arrayit Corporation. On or prior to June 30, 2016, AVDX and AMBS shall have reached an agreement with Arrayit Corporation ("Arrayit" regarding the OvaDx technology transfer, share ownership and restrictions on sales or transfer of shares of the AVDX Common Stock held, which could result in, among other things, (i) the cancellation of all agreements with Arrayit including, but not limited to, the Technology Assignment Agreement, dated July 18, 2009, share exchange agreement (ii) entry into a lockup agreement for all shares of Buyer Common Stock held by Arrayit and/or (iii) any such other agreements as the parties may agree upon on or after the Closing."
What was the resolution to this issue? Was an agreement reached? Do we (meaning AVDX) still own OvaDx?
2. AMBS issued an 8K saying that the board approved a change to the conversion price of the Series E and H to $0.05 and indicated that amendments to each of the Series E and Series H Certificates of Designation would be filed once the proper consents were obtained from the holders of the Series E and Series H Preferred Stock.
These amendments have not been filed. Is there any issue in obtaining the consents? What's the hold-up? Will they agree to the new $0.05 conversion price?
3. Exclusivity with our potential JV partner expired on Aug 29.
Was it extended?
4. The 10Q is extremely late.
When will it be filed?
5. On August 1, Lonza said retraining would be complete in 3-4 weeks. It has been over 5 weeks.
Is retraining done? When can we expect an update?
Seems like time for a tweet, blog or SEC filing from Gerald on these issues.
1. AVDX filed its Exchange Agreement with the SEC and it included this:
"Agreement regarding Arrayit Corporation. On or prior to June 30, 2016, AVDX and AMBS shall have reached an agreement with Arrayit Corporation ("Arrayit" regarding the OvaDx technology transfer, share ownership and restrictions on sales or transfer of shares of the AVDX Common Stock held, which could result in, among other things, (i) the cancellation of all agreements with Arrayit including, but not limited to, the Technology Assignment Agreement, dated July 18, 2009, share exchange agreement (ii) entry into a lockup agreement for all shares of Buyer Common Stock held by Arrayit and/or (iii) any such other agreements as the parties may agree upon on or after the Closing."
What was the resolution to this issue? Was an agreement reached? Do we (meaning AVDX) still own OvaDx?
2. AMBS issued an 8K saying that the board approved a change to the conversion price of the Series E and H to $0.05 and indicated that amendments to each of the Series E and Series H Certificates of Designation would be filed once the proper consents were obtained from the holders of the Series E and Series H Preferred Stock.
These amendments have not been filed. Is there any issue in obtaining the consents? What's the hold-up? Will they agree to the new $0.05 conversion price?
3. Exclusivity with our potential JV partner expired on Aug 29.
Was it extended?
4. The 10Q is extremely late.
When will it be filed?
5. On August 1, Lonza said retraining would be complete in 3-4 weeks. It has been over 5 weeks.
Is retraining done? When can we expect an update?
Seems like time for a tweet, blog or SEC filing from Gerald on these issues.
(9)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼